The Exon 20 Group is a laser-focused, multi-stakeholder, global coalition of patients, care partners, family members, thoracic/medical oncologists, scientists, molecular profiling labs, and pharmaceutical companies and biotechs with the mission of converting exon 20 insertion mutations into chronic diseases and then curing them. Join us!
Since ICAN and the Exon 20 Group strictly adhere to all HIPAA (Health Insurance Portability and Accountability Act of 1996) provisions to protect your privacy, during our initial intake call/meeting with you, we will review, and you will have a chance to discuss with us our Navigation Consent forms.
We never sell your information and only release information with your explicit permission (for example, when setting up a second opinionat your request, applying for expanded access/compassionate use, or inquiring about a clinical trial).
The Exon 20 Group (https://exon20group.org) is a special initiative of
ICAN, International Cancer Advocacy Network.
*Marcia K. Horn is President and CEO of ICAN International Cancer Advocacy Network and
Executive Director of the Exon 20 Group.